SG Americas Securities LLC Makes New Investment in Regulus Therapeutics Inc. (NASDAQ:RGLS)

SG Americas Securities LLC bought a new stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 20,800 shares of the biopharmaceutical company’s stock, valued at approximately $33,000.

Several other large investors have also modified their holdings of the stock. Renaissance Technologies LLC grew its position in Regulus Therapeutics by 56.4% in the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 42,600 shares during the last quarter. Rhumbline Advisers acquired a new stake in shares of Regulus Therapeutics in the 2nd quarter worth $136,000. Opaleye Management Inc. purchased a new stake in shares of Regulus Therapeutics in the first quarter valued at about $490,000. Bank of New York Mellon Corp acquired a new position in shares of Regulus Therapeutics during the second quarter worth about $352,000. Finally, Vanguard Group Inc. raised its holdings in Regulus Therapeutics by 158.4% during the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after purchasing an additional 453,784 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Price Performance

RGLS opened at $1.61 on Wednesday. The stock’s 50 day simple moving average is $1.59 and its 200 day simple moving average is $1.88. The stock has a market cap of $105.41 million, a P/E ratio of -1.28 and a beta of 1.62. Regulus Therapeutics Inc. has a 1-year low of $1.08 and a 1-year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.17). Research analysts expect that Regulus Therapeutics Inc. will post -0.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RGLS has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a report on Tuesday, October 8th. Oppenheimer restated an “outperform” rating and issued a $7.00 price target on shares of Regulus Therapeutics in a research note on Wednesday, August 14th. Finally, StockNews.com upgraded Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.